GALECTIN THERAPEUTICS INC 8K

Galectin Therapeutics eliminated about $105.8 million of related-party debt by converting five credit-facility notes held by its Chairman into common stock, materially delevering its balance sheet while issuing 34.4 million new shares.

Galectin Therapeutics Inc. announced that its Chairman and largest stockholder, Richard E. Uihlein, converted all outstanding principal and accrued interest under five of the company’s line of credit facilities into 34,376,167 shares of common stock effective July 31, 2026, eliminating approximately $105.8 million of debt (including $91.0 million of principal and $14.8 million of interest) at a blended average conversion price of about $3.07 per share, significantly strengthening the company’s balance sheet while increasing shares outstanding to 100,849,644 and leaving a separate, undrawn $10 million supplemental credit facility from December 19, 2025 available for future financing.

Filing Facts

CIK

1133416

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-031058

Alert Tier

7